Advances in Chronic Airway Disease

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (31 August 2022) | Viewed by 4816

Special Issue Editor


E-Mail Website
Guest Editor
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan
Interests: asthma; chronic obstructive pulmonary disease; respiratory medicine; sleep apnea; critical care medicine; transcriptomic analysis; microRNA; artificial intelligence

Special Issue Information

Dear Colleagues,

Chronic airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), are prevalent chronic inflammatory pulmonary diseases with high personal and social impacts. Exposome, microbiome, genome, and epigenome are all important in the pathogenesis. Bronchial epithelial cells are the frontline barrier against inhaled noxious agents and microorganisms, and may be responsible for inducing the downstream cellular and non-cellular responses in the airway microenvironment. Immune cells may be recruited into the microenvironment, secreting mediators, such as immunoglobulin E, cytokines, and chemokines, and affect other cells in the microenvironment, such as fibroblasts, smooth muscle cells, and endothelial cells. Collectively, these cells and their interactions contribute to the pathogenesis of chronic airway disease. With wider use of newer study tools, such as next-generation sequencing and single-cell analyses, we are able to understand the detailed pathogenic mechanisms in the airway microenvironment.

Chronic airway disease presents with various endotypes and phenotypes. Results of pulmonary function tests are important in the diagnosis, as well as in assessing the risk of exacerbation. Overlaps between several types of chronic airway disease are usually associated with poorer control and require sophisticated care. The comorbidities, such as sleep apnea, gastrointestinal dysfunction, depression, osteoporosis, metabolic syndrome, and cardiovascular disorders, should also be managed properly to achieve better disease control. In addition to bronchodilators and inhaled corticosteroids, novel therapeutic agents, particularly biologic agents, are available for the treatment of chronic airway disease. The identification of various treatable traits, which help us understand the endotypes and phenotypes through validated biomarkers, provides us a better chance to tailor precision medicine for patients.

This Special Issue will offer an overview of the recent advancements in the field of chronic airway diseases. Outstanding experts interested in this Special Issue are invited to submit original manuscripts and reviews dealing with any of the aforementioned aspects.

Dr. Ming-Ju Tsai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • asthma
  • chronic obstructive pulmonary disease
  • bronchiectasis
  • microenvironment
  • inflammation
  • microRNA
  • comorbidity
  • treatable trait
  • precision medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 1024 KiB  
Review
Pharmacological Strategies and Recent Advancement in Nano-Drug Delivery for Targeting Asthma
by Aftab Ahmad
Life 2022, 12(4), 596; https://doi.org/10.3390/life12040596 - 18 Apr 2022
Cited by 17 | Viewed by 4272
Abstract
With a high prevalence globally, asthma is a severe hazard to human health, as well as an economic and social burden. There are now novel therapies available for asthma with the use of nanotechnology. Recent developments in nanoscience and medicine have encouraged the [...] Read more.
With a high prevalence globally, asthma is a severe hazard to human health, as well as an economic and social burden. There are now novel therapies available for asthma with the use of nanotechnology. Recent developments in nanoscience and medicine have encouraged the creation of inhalable nanomedicines that can enhance the efficacy, patient compliance, and life quality for sufferers of asthma. Nanocarriers for asthma therapy, including liposomes, micelles, polymers, dendrimers, and inorganics, are presented in depth in this study as well as the current research status of these nanocarriers. Aerosolized nanomaterial-based drug transport systems are currently being developed, and some examples of these systems, as well as prospective future paths, are discussed. New research subjects include nano-modification of medicines and the development of innovative nano-drugs. Clinical experiments have proven that nanocarriers are both safe and effective. Before nanotherapy can be applied in clinical practice, several obstacles must be addressed. We look at some of the most recent research discoveries in the subject of nanotechnology and asthma therapy in this article. Full article
(This article belongs to the Special Issue Advances in Chronic Airway Disease)
Show Figures

Figure 1

Back to TopTop